Efficacy of arbidol in COVID-19 patients:A retrospective study  

作　　者：Shuo Wei Sha Xu Yun-Hu Pan 

机构地区：[1]Department of Infectious Diseases,Fujian Provincial Hospital,Fujian Medical University,Fuzhou 350000,Fujian Province,China [2]Department of Infectious Diseases,Jinyintan Hospital,Wuhan 430000,Hubei Province,China [3]Department of Respiratory Medicine,907 Hospital of the Joint Logistics Team,Nanping 353000,Fujian Province,China

出　　处：《World Journal of Clinical Cases》2021年第25期7350-7357,共8页世界临床病例杂志

摘　　要：To date,no treatment has proven to be absolutely effective for coronavirus disease 2019(COVID-19)patients,and further research is necessary.As a traditional antiviral drug,arbidol was widely used in Wuhan at the beginning of the COVID-19 epidemic and is of increasing interest for treating COVID-19 based on in vitro data suggesting activity against severe acute respiratory syndrome(SARS).Although arbidol has been widely used in China to treat COVID-19 patients,clinical trials to date have not clearly substantiated this approach.AIM To evaluate the efficacy of arbidol for COVID-19.METHODS A retrospective study was conducted on 132 moderate and severe COVID-19 patients admitted to Jinyintan Hospital and Huoshenshan Hospital(officially designated for COVID-19 treatment)from February to March 2020 in Wuhan,China.This study mainly evaluated the efficacy of arbidol in patients with COVID-19 in the early stage of the SARS coronavirus 2 epidemic.Arbidol was administered at a dose of 200 mg,three times a day,with a 10-d course to adults not receiving any other drugs.Due to the shortage of beds at the time,not every patient could be admitted immediately.We looked for the early stages of the sudden outbreak,places of limited medical resources,limited ward beds,and delayed admission;thus,some patients naturally fit into the control group who did not receive any antiviral drugs.Out of the 132 patients,72 received arbidol treatment,and 60 did not.We compared the disease course of the two groups and explored the predictors of extended disease duration.RESULTS Seventy-two patients commenced arbidol,and 60 patients did not receive arbidol treatment.The disease duration in the former group was shorter(23.42±6.92 vs 29.60±6.49,P<0.001).Multivariate regression analysis showed that the risk of a prolonged course of disease increased by 7.158 times in the non-arbidol treatment group.Ferritin>483.0 ng/mL and lactate dehydrogenase(LDH)>237.5 U/L were found to be independent risk factors for protracted cases,with the risk of an extended

关 键 词：COVID-19 SARS-CoV-2 ARBIDOL TREATMENT ANTIVIRAL 

分 类 号：R563.1[医药卫生—呼吸系统]